Article
Clinical impact of gene mutations and lesions detected by SNP-array karyotyping in acute myeloid leukemia patients in the context of gemtuzumab ozogamicin treatment: results of the ALFA-0701 trial.
Oncotarget - 28 Feb 2014
Renneville Aline, Abdelali Raouf Ben, Chevret Sylvie, Nibourel Olivier, Cheok Meyling, Pautas Cécile, Duléry Rémy, Boyer Thomas, Cayuela Jean-Michel, Hayette Sandrine, Raffoux Emmanuel, Farhat Hassan, Boissel Nicolas, Terre Christine, Dombret Hervé, Castaigne Sylvie, Preudhomme Claude
Abstract excerpt
We recently showed that the addition of fractionated doses of gemtuzumab ozogamicin (GO) to standard chemotherapy improves clinical outcome of acute myeloid leukemia (AML) patients. In the present study, we performed mutational analysis of 11 genes (FLT3, NPM1, CEBPA, MLL, WT1, IDH1/2, RUNX1, ASX...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.